Pathway Therapeutics, Inc. — Form D
Pathway Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2011-06-07. The offering totals $9.7M, of which $7.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2011-06-07
- Form: D
- Accession: 0001498495-11-000001
- Industry: Biotechnology
- Exemptions: 06
- Total offering: $9.7M
- Amount sold: $7.5M
- Remaining: $2.2M
- Investors: 4
- Date of first sale: 2011-05-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-160907
Issuer
- Name: Pathway Therapeutics, Inc.
- CIK: 0001498495
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2010
- Address: 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158
- Phone: 415.643.4473
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Will Charles | Director | Cleveland, OH |
| Mark Harvey | Director | Eden Prairie, MN |
| MARK PERRY | Director | SANTA MONICA, CA |
| Julie Cherrington | Director | San Francisco, CA |
| Julie Cherrington | Executive Officer | San Francisco, CA |
| Joshua Funder | Director | Stamford, CT |
| Carrie Hillyard | Director | Brisbane, C3 |
| Hilary Lewis | Director | Auckland, Q2 |
| Paul Goddard | Director | San Francisco, CA |
| Hillary Lewis | Director | Auckland, Q2 |
Other filings by this issuer (3)
More